StartsideABBV34 • BVMF
add
Abbvie Inc BDR
Forrige sluttkurs
62,36 R$
Dagsintervall
62,76 R$ - 64,74 R$
Årsintervall
40,77 R$ - 74,95 R$
Markedsverdi
312,70 mrd. USD
Gjennomsnittlig volum
1,45k
I nyhetene
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Omsetning | 14,46 mrd. | 3,83 % |
Driftskostnader | 6,07 mrd. | 21,67 % |
Nettoomsetning | 1,56 mrd. | −12,20 % |
Netto resultatmargin | 10,80 | −15,43 % |
Fortjeneste per aksje | 3,00 | 1,69 % |
EBITDA | 6,26 mrd. | −8,02 % |
Faktisk avgiftssats | 24,95 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 7,28 mrd. | −45,18 % |
Totale aktiva | 143,42 mrd. | 5,29 % |
Totale passiva | 137,35 mrd. | 10,68 % |
Total egenkapital | 6,07 mrd. | — |
Utestående aksjer | 1,77 mrd. | — |
P/B-forhold | 18,29 | — |
Avkastning på aktiva | 7,33 % | — |
Avkastning på kapital | 13,48 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | 1,56 mrd. | −12,20 % |
Kontantstrøm fra drift | 5,45 mrd. | −28,08 % |
Kontanter fra investering | −8,26 mrd. | −2 137,40 % |
Kontanter fra finansiering | −3,07 mrd. | −15,45 % |
Netto kontantstrøm | −5,87 mrd. | −229,70 % |
Fri kontantstrøm | 5,50 mrd. | −26,01 % |
Om
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira, administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.
It developed Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases. Its other major products include Botox, Imbruvica to treat cancer, Rinvoq to treat arthritis, Venclexta to treat leukemia and lymphoma, Vraylar to treat schizophrenia and bipolar disorder, and Mavyret to treat Hepatitis C. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis.
In 2023, Humira began facing competition from a biosimilar developed by Amgen. Wikipedia
Grunnlagt
1. jan. 2013
Hovedkvarter
Nettsted
Ansatte
50 000
